Literature DB >> 17387146

Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization.

Qingqing Ding1, Xianghuo He, Jung-Mao Hsu, Weiya Xia, Chun-Te Chen, Long-Yuan Li, Dung-Fang Lee, Jaw-Ching Liu, Qing Zhong, Xiaodong Wang, Mien-Chie Hung.   

Abstract

Apoptosis is critical for embryonic development, tissue homeostasis, and tumorigenesis and is determined largely by the Bcl-2 family of antiapoptotic and prosurvival regulators. Here, we report that glycogen synthase kinase 3 (GSK-3) was required for Mcl-1 degradation, and we identified a novel mechanism for proteasome-mediated Mcl-1 turnover in which GSK-3beta associates with and phosphorylates Mcl-1 at one consensus motif ((155)STDG(159)SLPS(163)T; phosphorylation sites are in italics), which will lead to the association of Mcl-1 with the E3 ligase beta-TrCP, and beta-TrCP then facilitates the ubiquitination and degradation of phosphorylated Mcl-1. A variant of Mcl-1 (Mcl-1-3A), which abolishes the phosphorylations by GSK-3beta and then cannot be ubiquitinated by beta-TrCP, is much more stable than wild-type Mcl-1 and able to block the proapoptotic function of GSK-3beta and enhance chemoresistance. Our results indicate that the turnover of Mcl-1 by beta-TrCP is an essential mechanism for GSK-3beta-induced apoptosis and contributes to GSK-3beta-mediated tumor suppression and chemosensitization.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17387146      PMCID: PMC1900029          DOI: 10.1128/MCB.00620-06

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  50 in total

Review 1.  Apoptosis induced by death receptors.

Authors:  P Schneider; J Tschopp
Journal:  Pharm Acta Helv       Date:  2000-03

Review 2.  Death receptors couple to both cell proliferation and apoptosis.

Authors:  Ralph C Budd
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

3.  Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death.

Authors:  D A Cross; A A Culbert; K A Chalmers; L Facci; S D Skaper; A D Reith
Journal:  J Neurochem       Date:  2001-04       Impact factor: 5.372

4.  Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3beta.

Authors:  M Li; X Wang; M K Meintzer; T Laessig; M J Birnbaum; K A Heidenreich
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

5.  Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation.

Authors:  C Desbois-Mouthon; A Cadoret; M J Blivet-Van Eggelpoël; F Bertrand; G Cherqui; C Perret; J Capeau
Journal:  Oncogene       Date:  2001-01-11       Impact factor: 9.867

6.  Mcl-1 deficiency results in peri-implantation embryonic lethality.

Authors:  J L Rinkenberger; S Horning; B Klocke; K Roth; S J Korsmeyer
Journal:  Genes Dev       Date:  2000-01-01       Impact factor: 11.361

Review 7.  GSK3 takes centre stage more than 20 years after its discovery.

Authors:  S Frame; P Cohen
Journal:  Biochem J       Date:  2001-10-01       Impact factor: 3.857

8.  Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal.

Authors:  M Hetman; J E Cavanaugh; D Kimelman; Z Xia
Journal:  J Neurosci       Date:  2000-04-01       Impact factor: 6.167

Review 9.  MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis.

Authors:  R W Craig
Journal:  Leukemia       Date:  2002-04       Impact factor: 11.528

10.  Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo.

Authors:  J Deng; W Xia; M C Hung
Journal:  Oncogene       Date:  1998-10-29       Impact factor: 9.867

View more
  203 in total

1.  FBXO4 inhibits lung cancer cell survival by targeting Mcl-1 for degradation.

Authors:  C Feng; F Yang; J Wang
Journal:  Cancer Gene Ther       Date:  2017-08-04       Impact factor: 5.987

2.  Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors.

Authors:  Gregory J Gores; Scott H Kaufmann
Journal:  Genes Dev       Date:  2012-02-15       Impact factor: 11.361

3.  Stalling in mitosis and releasing the apoptotic brake.

Authors:  Manabu Kurokawa; Sally Kornbluth
Journal:  EMBO J       Date:  2010-07-21       Impact factor: 11.598

4.  MCL-1 is a stress sensor that regulates autophagy in a developmentally regulated manner.

Authors:  Marc Germain; Angela P Nguyen; J Nicole Le Grand; Nicole Arbour; Jacqueline L Vanderluit; David S Park; Joseph T Opferman; Ruth S Slack
Journal:  EMBO J       Date:  2010-12-07       Impact factor: 11.598

5.  DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells.

Authors:  Naoe Taira; Rei Mimoto; Morito Kurata; Tomoko Yamaguchi; Masanobu Kitagawa; Yoshio Miki; Kiyotsugu Yoshida
Journal:  J Clin Invest       Date:  2012-02-06       Impact factor: 14.808

Review 6.  Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members.

Authors:  Joseph T Opferman
Journal:  FEBS J       Date:  2015-09-15       Impact factor: 5.542

Review 7.  The impact of phosphatases on proliferative and survival signaling in cancer.

Authors:  Goutham Narla; Jaya Sangodkar; Christopher B Ryder
Journal:  Cell Mol Life Sci       Date:  2018-05-03       Impact factor: 9.261

8.  Deubiquitinase USP9x confers radioresistance through stabilization of Mcl-1.

Authors:  Donatella Trivigno; Frank Essmann; Stephan M Huber; Justine Rudner
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

Review 9.  AKT/PKB Signaling: Navigating the Network.

Authors:  Brendan D Manning; Alex Toker
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

10.  mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation.

Authors:  Junghui Koo; Ping Yue; Xingming Deng; Fadlo R Khuri; Shi-Yong Sun
Journal:  Mol Cell Biol       Date:  2015-04-27       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.